HIGHLIGHTS
- who: Maria M. Alves from the DepartmentErasmus University have published the paper: PAK2 is an effector of TSC1/2 signaling independent of mTOR and a potential therapeutic target for Tuberous Sclerosis Complex, in the Journal: Scientific Reports Scientific Reports
- what: The authors provide evidence that PAK2 signaling constitutes a second signal_transduction module downstream of the TSC1-TSC2-RHEB signal_transduction complex, whose inhibition may be potentially useful, as strong PAK2 activation appears to be a characteristic of human disease, at least in the brain. All patients included in this study fulfilled the diagnostic criteria for TSC50 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.